[Comparison of screening-detected and symptomatic lung cancer patients].
Survival rates were studied in 416/27 screening-detected and 1,099/188 symptomatic patients with non-small cell lung cancer (NSCLC)/small cell lung cancer (SCLC). Screening-detected patients with both NSCLC and SCLC had earlier stage disease, showed better PS distribution, and a greater part of the patients underwent standard therapy than the symptomatic cohort with a significant difference. Median survival time, 5- and 10-year survival rates were 1,220 days, 44.4% and 34.9%, respectively, in the screening-detected patients, and 248 days, 11.3% and 7.5%, respectively, in the symptomatic patients with NSCLC. They were 584 days, 21.2% and 15.9%, respectively, in the screening-detected patients, and 257 days, 4.8% and 2.3% in the symptomatic patients with SCLC.
Nishiwaki
Y
Y
Dept. of Thoracic Oncology, National Cancer Center Hospital East, Chiba Japan.
Hojo
F
F
Omatsu
H
H
Nagai
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000401:mortality / Q000517:prevention & control; D018288:Carcinoma, Small Cell / Q000175:diagnosis* / Q000401:mortality / Q000517:prevention & control; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000517:prevention & control; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D015996:Survival Rate